Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. with Series of Stock Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of open market purchases between March 11 and March 13, 2025.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., have reported changes in their beneficial ownership of Zymeworks Inc. common stock.
• Between March 11 and March 13, 2025, EcoR1 Capital Fund Qualified, L.P. purchased a total of 1,081,986 shares of Zymeworks Inc. common stock.
• The purchases were made in multiple transactions at varying weighted average prices: $11.4935 on March 11 for 320,690 shares, $12.2479 on March 12 for 292,934 shares, and $12.4846 on March 13 for 468,356 shares.
• Following these transactions, EcoR1 Capital Fund Qualified, L.P. beneficially owns 15,749,195 shares of Zymeworks Inc. common stock.
• EcoR1 Capital, LLC is the general partner and investment advisor of private funds, including EcoR1 Capital Fund Qualified, L.P., and may be deemed to indirectly beneficially own the shares.
• Oleg Nodelman, as the manager and controlling owner of EcoR1 Capital, LLC, may also be deemed to indirectly beneficially own the shares.
• Both EcoR1 Capital, LLC and Oleg Nodelman disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests.
• Oleg Nodelman is a director of Zymeworks Inc., and Scott Platshon, an employee of EcoR1, also serves as a director.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a major shareholder is increasing their stake, indicating confidence in the company. However, it's a routine filing, so the impact is limited.

Positives

• EcoR1 Capital's increased investment in Zymeworks Inc. could be interpreted as a positive signal regarding the company's prospects.
• The purchases demonstrate EcoR1's confidence in Zymeworks' future performance.

Risks

• The document does not explicitly mention any risks.
• However, it is important to note that increased ownership by a single entity could potentially lead to greater influence over the company's decisions.

Industry Context

This announcement reflects investment activity in the biotechnology sector, where firms like Zymeworks are often subject to significant ownership changes as investors adjust their positions based on clinical trial results, regulatory milestones, and market conditions.

Comparison to Industry Standards

• Comparing EcoR1's investment to similar moves by other biotech-focused funds like Orbimed or RA Capital Management, the size of the stake increase is notable but not uncommon for firms with strong conviction in a company's pipeline.
• Similar ownership filings can be seen with companies like Amgen, Regeneron, and Biogen, where institutional investors frequently adjust their holdings based on company performance and market sentiment.

Stakeholder Impact

• Shareholders may view EcoR1's increased stake as a positive signal.
• Employees may feel more secure knowing a major investor is confident in the company's future.

Key Dates